Oxford Biomedica (LSE:OXB)
About
Last updated 21-09-2021, 04:30:00pm BSTRelated Articles
-
Top British stocks for July
We asked our freelance writers to share their top British stocks for July, including Smith & Nephew, Motorpoint and TI Fluid Systems. Read More »
-
Will the Oxford Biomedica share price keep on climbing?
The Oxford Biomedica share price is surging after extending its deal with AstraZeneca. Zaven Boyrazian investigates if this momentum can continue. Read More »
-
Oxford Biomedica’s share price hits record peaks as it upgrades forecasts!
The Oxford Biomedica share price has roared to new all-time peaks as vaccine orders from AstraZeneca increase. Here are the key points. Read More »
-
Want to be a millionaire? I’d follow Warren Buffett’s example and buy cheap shares
Warren Buffett made his fortune in the stock market. Zaven Boyrazian explains how he did it, and how you can become a millionaire by... Read More »
-
Top British stocks for January 2021
We asked our freelance writers to share their top British stocks for January, including Rio Tinto, Safestore and IG Group. Read More »
-
AstraZeneca’s Covid-19 vaccine approved! Here’s what I’d do now
Approval for AstraZeneca’s vaccine brings the UK a step closer to winning the fight against Covid-19. But is there a better investment opportunity than... Read More »
-
Covid-19 vaccine: 1 biotech stock that profits from AstraZeneca’s success
Another Covid-19 vaccine may soon be available from AstraZeneca. Zaven Boyrazian analyses the results and finds a larger opportunity for a biotech stock. Read More »
-
I’d buy these 2 growth stocks for explosive returns!
Looking for top UK shares to buy now? These two biotech growth stocks have been generating explosive returns for many years. Read More »
-
Did Oxford Biomedica just find a new treatment for Parkinson’s disease?
Zaven Boyrazian takes another look at Oxford Biomedica after promising results on its Parkinson’s disease treatment were announced. Read More »
-
1 hidden growth stock I think can become a leader in this $14bn industry
Biotech has become a powerful source of growth for big pharma. Zaven Boyrazian takes a closer look at a growth stock that could capitalise... Read More »